High-intensity statin is named as an intervention in 6 current clinical trials in our South Korea and China registers. 5 are recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is Yonsei University (2). The most-studied condition is Acute Coronary Syndrome.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Acute Coronary Syndrome | 1 |
| Hyperlipidemias | 1 |
| Percutaneous Coronary Intervention | 1 |
| Cardiovascular Events | 1 |
| Cardiovascular Diseases | 1 |
| Coronary Artery Disease Requiring Coronary Revascularization With Newer Generation DES Implantation | 1 |
| Coronary Artery Calcification | 1 |
| Metabolic Syndrome | 1 |
| Dyslipidemias | 1 |
| Renal Insufficiency | 1 |
| Atherosclerosis | 1 |
| Dyslipidemia | 1 |
| Hypercholesterolemia | 1 |
| ASCVD | 1 |
| Diabetes | 1 |
| Statin | 1 |
| Lead sponsor | Trials |
|---|---|
| Yonsei University | 2 |
| Nanjing First Hospital, Nanjing Medical University | 1 |
| Jung-min Ahn | 1 |
| Samsung Medical Center | 1 |
| Korea University Anam Hospital | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in South Korea | 5 | 5 |
| Clinical trials in China | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
6 current trials in our South Korea and China registers name High-intensity statin as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 5 of the 6 trials are recruiting: 5 with sites in South Korea. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Yonsei University (2), Nanjing First Hospital, Nanjing Medical University (1), Jung-min Ahn (1) and Samsung Medical Center (1), among 5 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how High-intensity statin works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how High-intensity statin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists High-intensity statin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.